The TP53 gene is most frequently mutated in solid tumors[27] – the highest percentage of mutations in this study was detected in colorectal cancer (19/31; 61.3%) and glioma (25/97; 25.8%), in hematological malignancies these mutations are less frequent (in this study only 8.7% samples diagnosed with acute myeloid leukemia were mutated), but often strongly correlated with unfavorable prognosis and resistance to therapy[28, 29]. This evidence concerns the gene TP53 and central nervous system cancer.